Search
Home






Property Submission

FORM 4

Check this box if you are no longer subject to section 16, the obligations of Form 4 or Form 5 may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549STATEMENT OF CHANGES IN THE EFFECTIVE BENEFICIARIES OF THE SHARES Filed under Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number: 3235-0287 Expires: January 31, 2005 Estimated average charge hours per response…0.5

1. Name and address of reporting person *

Klein Pamela M.

2. Name of issuer and stock symbol or trading symbol
F-star Therapeutics, Inc. [FSTX]

5. Relationship between the reporting person(s) and the issuer
(Check all that apply)

__X__ Director

_____ 10% Owner

_____ Officer (indicate title below)

_____ Other (specify below)

(Last)

(First)

(Environment)

C/O F-STAR THERAPEUTICS, INC., EDDEVA B920, BABRAHAM RESEARCH CAMPUS

3. Date of first transaction (month/day/year)

(Street)

CAMBRIDGE

X0

CB22 3AT

4. In case of modification, date of filing of the original (month/day/year)

6. Individual or joint/group filing (check applicable row)
_X_ Form filed by a reporting person
___ Form filed by more than one declarant

Table I – Non-derivative securities acquired, sold or beneficially owned

1. Title of guarantee

2. Transaction date (month/day/year)

2A. Deemed execution date, if applicable (month/day/year)

3. Transaction code

4. Securities acquired (A) or transferred (D)

5. Amount of securities beneficially owned as a result of the reported transaction(s)

6. Form of ownership: direct (D) or indirect (I)

7. Nature of Indirect Beneficial Ownership

Coded

V

Rising

(A) or (D)

Price

Table II – Beneficial ownership derivative securities (for exampleputs, calls, warrants, options, convertible securities)
(for exampleputs, calls, warrants, options, convertible securities)

1. Title of derivative title

2. Conversion or exercise price of the derivative security

3. Transaction date (month/day/year)

3A. Deemed execution date, if applicable (month/day/year)

4. Transaction code

5. Number of derivative securities acquired (A) or sold (D)

6. Exercise date and expiry date

7. Title and amount of the securities underlying the derivative securities

8. Price of derivative securities

9. Number of derivative securities beneficially owned as a result of reported transactions

10. Form of ownership of derivative securities: direct (D) or indirect (I)

11. Nature of Indirect Beneficial Ownership

Coded

V

(A)

(D)

Exercise date

Expiration date

Title

Amount or number of shares

Reporting owners

Name/address of declaring owner Relationships

Director

10% Owner

Officer

Other

Klein Pamela M.
C/O F-STAR THERAPEUTICS, INC.
EDDEVA B920, BABRAHAM RESEARCH CAMPUS
CAMBRIDGE, X0CB22 3AT

X

Signatures

/s/ Darlene Deptula-Hicks, practicing lawyer

2022-06-22

**Signature of declaring person

Date

Explanation of answers:

If the form is completed by several declarants, see

Section 5(b)(v).

(**) Intentional misrepresentation or omission of facts are federal criminal offenses. See

18 USC 1001 and 15 USC 78ff(a).

(1)

These options were granted as part of the Issuer’s compensation program for non-employee directors.

(2)

Shares under the award will vest in 12 equal monthly installments over a one-year period through June 16, 2023, subject to the reporting person’s continued service as a director of the company. Note: Submit three copies of this form, one of which must be manually signed. If space is insufficient, See

Instruction 6 for the procedure. Potential individuals who need to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Disclaimer F-star Therapeutics Inc. published this content on June 22, 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unmodified, onJun 23, 2022 04:34:07 UTC

.

Public now 2022

All news about F-STAR THERAPEUTICS, INC.

Analyst Recommendations on F-STAR THERAPEUTICS, INC.

2022 sales
6.15M
–
– Net income 2022
-52.8M
–
– Net debt 2022
–
–
– PER 2022 ratio
-1.65x 2022 return
– Capitalization
85.8 million
85.8 million
– capi. / Sales 2022
13.9x capi. / Sales 2023
21.5x # of employees
86 Floating

95.8%
Chart F-STAR THERAPEUTICS, INC.









F-star Therapeutics, Inc. Technical Analysis Chart | MarketScreener

F-star Therapeutics, Inc. Technical Analysis Chart | MarketScreener

Trending Technical Analysis F-STAR THERAPEUTICS, INC.
Short term Middle term
Long term Tendencies Bullish Neutral

Neutral


Please enable JavaScript in your browser settings to use dynamic graphics.

Sale
To buy Medium consensus
TO BUY Number of analysts
seven Last closing price
$3.98 Average target price
$25.71 Average Spread / Target

Please enable JavaScript in your browser settings to use dynamic graphics.


Related posts:

  1. Independence Holdings Corp. broadcasts the value of an preliminary public providing elevated by 435 million {dollars}
  2. Crystal Bridge Provides Transaction Update | 2021-03-08 | Press Releases
  3. Metamaterial Proclaims Extension of Letter of Transmittal Submission Deadline to March 31, 2021
  4. Digihost offers replace on proposed personal placement TSX Enterprise Alternate: DGHI